Global risk of coronary heart disease: Assessment and application

American Family Physician

Volumn 82, Issue 3, 2010, Pages 265-274

  Viera, Anthony J ^a   Sheridan, Stacey L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; DISEASE CONTROL; GLOBAL RISK ASSESSMENT; HUMAN; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; CORONARY ARTERY DISEASE; INCIDENCE; METHODOLOGY; PREDICTION AND FORECASTING; REVIEW; SURVIVAL RATE; UNITED STATES;

CORONARY DISEASE; HUMANS; INCIDENCE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 77956822052     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Lloyd-Jones D, Adams R, Carnethon M, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update [published correction appears in Circulation. 2009;119(3):e182]. Circulation. 2009;119(3):480-486.
2. Ford ES, Ajani UA, Croft JB, et al. explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-2398.
3. Cutler JA, Sorlie PD, Wolz M, thom t, Fields Le, Roccella eJ. trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52(5):818-827.
4. Thorndike AN, Regan S, Rigotti NA. The treatment of smoking by US physicians during ambulatory visits: 1994-2003. Am J Public Health. 2007;97(10):1878-1883.
5. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30(1):74-77.
6. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in AtP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol. 2007;17(7):548-555.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
8. Chobanian AV, Bakris GL, Black HR, et al.; national Heart, Lung, and Blood Institute Joint Committee on Prevention, Detection, evaluation, and treatment of High Blood Pressure; High Blood Pressure education Program Coordinating Committee. the seventh report of the Joint Committee on Prevention, Detection, and of High Blood Pressure: the JnC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA. 2003;289(19):2560-2572.
9. Expert Panel on Detection, and of High Blood Cholesterol in Adults. executive summary of the third report of the national Cholesterol education Program (nCeP) expert Panel on Detection, evaluation, and treatment of High Blood Cholesterol in Adults (Adult Panel III). JAMA. 2001;285(19):2486-2497.
10. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7160):823-828.
11. Buse JB, Ginsberg HN, Bakris GL, et al.; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114-126.
12. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000;321(7267):983-986.
13. Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services task Force. Am J Prev Med. 2003;25(2):151-158.
14. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control. the health benefits of smoking cessation: a report of the Surgeon General. Rockville, Md.: U.S. Dept. of Health and Human Services; 1990. DHHS publication no. (CDC) 90-8416.
15. US Preventive Services task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
16. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292(19):2350-2356.
17. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162(4):413-420.
18. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834.
19. Persell SD, Lloyd-Jones DM, Baker DW. National Cholesterol education Program risk assessment and potential for risk misclassification. Prev Med. 2006;43(5):368-371.
20. Pearson TA, Blair SN, Daniels SR, et al.; American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388-391.
21. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150(6):405-410.
22. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ. 1995;310(6985):975-978.
23. Meland E, Laerum E, Stensvold I. Assessment of coronary heart disease risk, I. A postal inquiry among primary care physicians. Fam Pract. 1994;11(2):117-121.
24. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services task Force. Ann Intern Med. 2002;136(2):161-172.
25. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res. 2008;8:60.
26. Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ. 2003;326(7383):251-252.
27. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ. 2000;320(7236):686-690.
28. Sheridan SL, Viera AJ, Krantz MJ, et al; Cardiovascular Health Intervention Research and translation network Group on Global Coronary Heart Disease Risk. the effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010;170(3):230-239.
29. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med. 2003;18(12):1039-1052.
30. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136.
31. Yang X, So WY, Kong AP, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol. 2008;101(5):596-601.
32. Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ. 1991;303(6805):744-747.
33. Mainous AG III, Koopman RJ, Diaz VA, Everett CJ, Wilson PW, Tilley BC. A coronary heart disease risk score based on patient-reported information. Am J Cardiol. 2007;99(9):1236-1241.
34. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187.
35. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004;291(21): 2591-2599.
36. Wallis EJ, Ramsay Le, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population [published correction appears in BMJ. 2000;320(7241):1034]. BMJ. 2000;320(7236):671-676.
37. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204-2211.
38. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166(13):1368-1373.
39. Ridker PM, Danielson E, Fonseca FA, et al.; JUPIteR Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
40. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services task Force. Ann Intern Med. 2009;151(7):496-507.
41. Cuite CL, Weinstein ND, Emmons K, Colditz G. A test of numeric formats for communicating risk probabilities. Med Decis Making. 2008;28(3):377-384.
42. Bogardus St Jr, Holmboe E, Jekel JF. Perils, pitfalls, and possibilities in talking about medical risk. JAMA. 1999;281(11):1037-1041.
43. Fair AK, Murray PG, Thomas A, Cobain MR. Using hypothetical data to assess the effect of numerical format and context on the perception of coronary heart disease risk. Am J Health Promot. 2008;22(4):291-296.
44. Covey J. A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Making. 2007;27(5):638-654.
45. Dr. Chris Cates' eBM Web site. http://nntonline.net/visualrx. Accessed April 28, 2010.
46. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324(7341):827-830.
47. Goodyear-Smith F, Arroll B, Chan L, Jackson R, Wells S, Kenealy T. Patients prefer pictures to numbers to express cardiovascular benefit from treatment. Ann Fam Med. 2008;6(3):213-217.
48. Stone ER, Yates JF, Parker AM. Effects of numerical and graphical displays on professed risk-taking behavior. J Exp Psychol Appl. 1997;3(4):243-256.
49. Feldman-Stewart D, Kocovski N, McConnell BA, Brundage MD, Mackillop WJ. Perception of quantitative information for treatment decisions. Med Decis Making. 2000;20(2):228-238.
50. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36.
51. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
52. Lotufo PA, Gaziano JM, Chae CU, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;161(2):242-247.
53. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161(14):1717-1723.
54. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142-148.
55. Sarnak MJ, Levey AS, Schoolwerth AC, et al.; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-2169.